CAMBRIDGE, Mass., Jan. 3, 2013 /PRNewswire/ -- Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced that Robert Gould, Ph.D., President and CEO of Epizyme, will present a company overview at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8 at 8 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA. The presentation will address advances made over the past year in Epizyme's proprietary product platform and pipeline of personalized therapeutics programs, as well as Epizyme's goals for 2013.
About Epizyme, Inc.
Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a class of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.
Epizyme has benchmark alliances with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma
SOURCE Epizyme, Inc.